1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
Backlog
URL Address
<a href="http://doi.org/10.1016/s0885-3924(03)00252-5" target="_blank" rel="noreferrer">http://doi.org/10.1016/s0885-3924(03)00252-5</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Safety of subcutaneous clodronate and efficacy in hypercalcemia of malignancy: a novel route of administration
Publisher
An entity responsible for making the resource available
Journal Of Pain And Symptom Management
Date
A point or period of time associated with an event in the lifecycle of the resource
2003
Subject
The topic of the resource
Female; Humans; Male; Cohort Studies; Analgesics; Treatment Outcome; Non-U.S. Gov't; Research Support; retrospective studies; Injections; Neoplasms/complications; Subcutaneous; Clodronate; Clodronic Acid/administration & dosage; Non-Narcotic/administration & dosage; Hypercalcemia/drug therapy/etiology
Creator
An entity primarily responsible for making the resource
Roemer-Becuwe C; Vigano A; Romano F; Neumann C; Hanson J; Quan HK; Walker P
Description
An account of the resource
Bisphosphonates have become standard treatment in management of malignancy-induced hypercalcemia and malignant bone pain. One obstacle to the routine use of bisphosphonates in palliative patients is that oral bisphosphonates have low bioavailability and a degree of gastrointestinal toxicity that may explain poor compliance. Intravenous administration can be cumbersome in patients admitted to long-term care settings or at home. We have developed and tested a new way of administering clodronate via subcutaneous infusion. This retrospective cohort study evaluated 150 patients admitted to a tertiary palliative care unit from May 1996 to May 2000 who received 254 subcutaneous infusions of clodronate for hypercalcemia or bony complications. Data were collected by chart review and specifically evaluated site toxicity and biochemistry. There was minimal local toxicity and only 2 infusions needed to be discontinued because of pain at the subcutaneous site. Clodronate showed efficacy in normalizing the serum calcium within 5 days post-infusion in 32 of 43 infusions given for hypercalcemia. This study shows that subcutaneous clodronate is safe and can lower serum calcium levels in malignant hypercalcemia.
2003
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/s0885-3924(03)00252-5" target="_blank" rel="noreferrer">10.1016/s0885-3924(03)00252-5</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Type
The nature or genre of the resource
Journal Article
2003
Analgesics
Backlog
Clodronate
Clodronic Acid/administration & dosage
Cohort Studies
Female
Hanson J
Humans
Hypercalcemia/drug therapy/etiology
Injections
Journal Article
Journal of Pain and Symptom Management
Male
Neoplasms/complications
Neumann C
Non-Narcotic/administration & dosage
Non-U.S. Gov't
Quan HK
Research Support
Retrospective Studies
Roemer-Becuwe C
Romano F
Subcutaneous
Treatment Outcome
Vigano A
Walker P